Please login to the form below

Not currently logged in
Email:
Password:

upadacitinib

This page shows the latest upadacitinib news and features for those working in and with pharma, biotech and healthcare.

EMA could follow FDA’s Xeljanz blood clot warning

EMA could follow FDA’s Xeljanz blood clot warning

The new safety signals could also cast a cloud over the entire JAK inhibitor class at risk, including AbbVie’s blockbuster-in-waiting upadacitinib, currently being assessed by the EMA and

Latest news

More from news
Approximately 1 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    It announced the filing of upadacitinib in the US and Europe on 20 December, with the filing of risankizumab expected early this year. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis, particularly from filgotinib.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....
International Women's Day - 8 March 2019
International Women's Day has been celebrated since its inception in 1911. But how far have we come?...

Infographics